ArticleJournal of molecular neuroscience : MN2026
Notch Signaling Regulates the Neuroprotective Effects of hUCMSCs in a Mouse Model of Cerebral Ischemia.
Article in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human umbilical cord mesenchymal stem cells (hUCMSCs) have shown promise for treating ischemic stroke (IS) by promoting neural repair. The Notch signaling pathway is known to regulate neural stem cell (NSC) proliferation and differentiation, but its role in hUCMSC-mediated neuroprotection remains unclear. This study aimed to evaluate the therapeutic effects of hUMSCs in a mouse model of middle cerebral artery occlusion (MCAO) and investigate the involvement of the Notch pathway. Fifth generation of hUCMSCs were characterized by flow cytometry. In vitro, hUCMSCs were induced to differentiate with or without DAPT (a Notch inhibitor) or Jagged1 (a Notch agonist), and neural differentiation was assessed by Nestin and MAP2 expression. In vivo, MCAO mice received hUCMSC transplantation, and NSC proliferation, differentiation, and neural repair were evaluated using BrdU/Nestin immunofluorescence, qRT-PCR, Western blot, mNSS scoring, TTC, Nissl, and TUNEL assays. HUCMSCs displayed typical mesenchymal markers (CD90, CD44, CD105, and CD73) and low expression of hematopoietic markers. In vitro, DAPT enhanced hUCMSC differentiation into neuron-like cells, while JAG1 reversed this effect, confirming the mechanistic role of Notch signaling. In MCAO mice, hUCMSC transplantation promoted NSC proliferation and differentiation in the SVZ, reduced infarct volume and water content, increased Nissl-positive neurons, decreased apoptotic cells, and lowered mNSS scores. Inhibition of Notch signaling further augmented these therapeutic effects. HUCMSCs promote neural differentiation and neuroprotection in ischemic brains, at least in part by modulating the Notch signaling pathway. These findings highlight hUCMSCs as a promising therapeutic strategy for IS.
Indexed as
Identifiers
42377662What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.